Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals announced that the US FDA has granted Priority Review for its New Drug Application (NDA) for revumenib for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
[Syndax Pharmaceuticals]
Press Release